Pancreatic Cancer Treatment Enters a New Chapter as Targeted Therapies Advance
An approved RAS-targeting drug and experimental cancer vaccines are raising hopes for more personalised treatment, says Medical College of Wisconsin oncologist Dr. Mandana Kamgar.
MILWAUKEE — Progress in targeting the biological mechanisms behind pancreatic cancer is giving researchers and patients fresh reason for optimism, although major challenges remain in treating a disease often diagnosed after it has spread.
Speaking to WUWM’s Audrey Nowakowski, Dr. Mandana Kamgar, a medical oncologist at the Medical College of Wisconsin, described a field increasingly guided by the molecular characteristics of individual tumours. Understanding those differences is helping researchers develop treatments aimed at the signals that allow cancer cells to grow.
One significant advance is daraxonrasib, marketed as Rasonque. The U.S. Food and Drug Administration approved the oral medicine on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy or are not candidates for multiagent systemic therapy. The drug inhibits RAS proteins involved in cancer growth.
Targeting the machinery behind tumour growth
KRAS mutations are a major driver of pancreatic cancer. Kamgar likened their effect to a growth switch that remains activated, allowing tumour cells to keep multiplying.
“Think of the KRAS as a growth switch turned on, and basically this drug is trying to turn that switch off,” she told WUWM.
Daraxonrasib represents one approach within a broader effort to interrupt those signals. Researchers are also exploring drugs with different mechanisms and levels of specificity, alongside combinations intended to strengthen or extend treatment responses.
According to Kamgar, approximately 60 patients at the Medical College of Wisconsin had received daraxonrasib over the preceding four to five months. She described encouraging responses in some patients, including tumour shrinkage on scans and reductions in tumour markers.
Those observations do not mean every patient will benefit or that responses will last indefinitely. The next challenge is to understand how to achieve more durable disease control and which treatment combinations can help.
Cancer vaccines remain under investigation
Another area of research involves therapeutic vaccines designed to help the immune system recognise and attack cancer cells.
Kamgar highlighted both personalised approaches, including mRNA vaccines, and ready-made peptide vaccines directed at mutations shared by groups of patients.
These vaccines are being studied as cancer treatments. Early findings have encouraged further trials, but their effectiveness and appropriate role in care remain under investigation.
Together, targeted medicines and vaccine research reflect a broader shift toward precision oncology: selecting treatment strategies informed by the biology of each patient’s cancer.
Clinical trials and informed treatment decisions
Despite that progress, pancreatic cancer remains difficult to detect early and challenging to treat. Symptoms can be vague, and many patients are diagnosed when the disease is already advanced.
Kamgar encouraged patients to discuss suitable clinical trials with their oncology teams. Participation may provide access to investigational treatments while helping researchers establish whether new approaches improve outcomes. Eligibility and suitability depend on the individual patient and the study.
She also pointed to the Seena Magowitz Foundation as a source of support and education for patients and caregivers. Its virtual meetings and annual Power of Us Conference connect families with researchers, specialists and others affected by pancreatic cancer.
For patients, the emerging treatment landscape offers more possibilities to discuss with their care teams. For researchers, the task is to translate growing knowledge of pancreatic cancer into benefits that reach more people and last longer.
Based on reporting by Audrey Nowakowski for WUWM 89.7 FM, published October 21, 2026. Regulatory information checked against the U.S. Food and Drug Administration.
Pancreatic cancer treatment is advancing through RAS-targeting medicines and experimental therapeutic vaccines. Daraxonrasib, marketed as Rasonque, received FDA approval in August 2026 for specified adults with metastatic pancreatic adenocarcinoma. Medical College of Wisconsin oncologist Dr. Mandana Kamgar highlights growing opportunities for personalised care while acknowledging that treatment responses vary.
